its Been said for a while that our unique Adapt tissue platform will be the competitive advantage that allows us to take significant market share from our competitors.
Furthermore it also allows development of new and unique products due to the unmatched qualities of the tissue.
There is a wave of data on the way to support those assertions and insurers and hospital systems can’t ignore it. Here’s one to kick things off...
https://academic.oup.com/icvts/advance-article/doi/10.1093/icvts/ivx413/4817448
its Been said for a while that our unique Adapt tissue platform...
-
- There are more pages in this discussion • 183 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.70 |
Change
-0.300(1.58%) |
Mkt cap ! $359.4M | |||
| Open | High | Low | Value | Volume |
| $19.00 | $19.00 | $18.62 | $180.3K | 9.596K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 475 | $18.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.91 | 100 | 1 |
View Market Depth
| Last trade - 14.41pm 20/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |